Syngene International forms a new subsidiary

The company shall be engaged in the business of manufacturing of pharmaceutical, bio-pharmaceutical and biological products of any kind

Syngene International to acquire stake in O2 Renewable Energy II

A special purpose vehicle (SPV) formed by O2 Energy SG Pte Ltd, for generation and supply of renewable power

Jubilant receives EIR from USFDA for its radiopharmaceuticals manufacturing facility Montreal Canada

With the receipt of the EIR, the inspection stands successfully closed.

Lupin launches Desvenlafaxine extended-release tablets in the US

Desvenlafaxine Extended-Release Tablets, 25 mg is a generic equivalent of Pristiq Extended-Release Tablets, 25 mg of PF PRISM C.V.

Granules India received ANDA approval for Guaifenesin and Pseudoephedrine Hydrochloride ER

Granules now have a total of 51 ANDA approvals from US FDA (49 Final approvals and 2 tentative approvals).

Olaparib approved in Japan as adjuvant treatment for patients with high recurrent risk breast cancer

First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint of the OlympiA trial, in these patients

Lupin and I'rom signs licensing agreement for Denosumab biosimilar for Japan

ENTOD organising nationwide campaign to encourage people to donate eyes

The initiative aims to reach out to more than 20 million people across the country and a number of social media influencers have also pledged to extend their whole-hearted support for the noble cause

Lupin receives approval from US FDA for Formoterol Fumarate Inhalation Solution

Formoterol Fumarate Inhalation Solution (RLD Perforomist) had estimated annual sales of US $282 million in the US

Eugia Pharma receives USFDA pproval for Medroxyprogesterone Acetate injectable suspension

The approved product has an estimated market size of around US $62 million for the twelve months ending June 2022 according to IQVIA